Last quarter (Q4 2023), Dermata Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Dermata Therapeutics's net income was $-2.13M. See Dermata Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 8.04M	$ 8.04M	$ 9.67M	$ 7.86M	$ 3.17M	$ 4.47M
Operating Income	$ -8.04M	$ -8.04M	$ -9.67M	$ -7.86M	$ -3.17M	$ -4.47M
Net Non Operating Interest Income Expense	$ 247.22K	$ 247.22K	$ 63.57K	$ -45.61K	$ -197.27K	$ -250.75K
Other Income Expense	-	-	-	-	$ 133.59K	-
Pretax Income	$ -7.79M	$ -7.79M	$ -9.61M	$ -7.90M	$ -3.24M	$ -4.72M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.79M	$ -7.79M	$ -9.61M	$ -10.46M	$ -3.24M	$ -4.72M
Basic EPS	$ -2.67	$ -2.67	$ -0.87	$ -2.43	$ -0.39	$ -0.57
Diluted EPS	$ -2.67	$ -2.67	$ -0.87	$ -2.43	$ -0.39	$ -0.57
Basic Average Shares	$ 11.68M	$ 2.92M	$ 11.05M	$ 3.25M	$ 8.33M	$ 8.33M
Diluted Average Shares	$ 11.68M	$ 2.92M	$ 11.05M	$ 3.25M	$ 8.33M	$ 8.33M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 8.04M	$ 8.04M	$ 9.67M	$ 7.86M	$ 3.17M	$ 4.47M
Net Income From Continuing And Discontinued Operation	$ -7.79M	$ -7.79M	$ -9.61M	$ -7.90M	$ -3.24M	$ -4.72M
Normalized Income	$ -3.03M	$ -6.16M	-	-	$ -3.37M	$ -4.72M
Interest Expense	-	-	-	-	$ 197.27K	$ 250.75K
EBIT	$ -7.79M	$ -7.79M	$ -9.67M	$ -7.86M	$ -3.04M	$ -4.47M
EBITDA	$ -7.79M	$ -7.79M	$ -9.67M	$ -7.84M	$ -3.04M	$ -4.47M

Currency in USD

Dermata Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing